Relay Therapeutics Inc (NASDAQ:RLAY) price on Thursday, January 16, rose 13.39% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $4.32.
A look at the stock’s price movement, the close in the last trading session was $3.81, moving within a range at $3.5 and $4.415. The beta value (5-Year monthly) was 1.675. Turning to its 52-week performance, $11.16 and $3.77 were the 52-week high and 52-week low respectively. Overall, RLAY moved -8.28% over the past month.
Relay Therapeutics Inc’s market cap currently stands at around $723.10 million, with investors looking forward to this quarter’s earnings report slated for in February.
Wall Street analysts have also projected the company’s year-on-year revenue to grow to 15.08M, representing a -40.98% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RLAY is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 5 recommend RLAY as a Buy and 1 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RLAY’s current price about -0.97% and -9.96% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.90, while 7-day volatility ratio is 25.47% and 10.97% in the 30-day chart. Further, Relay Therapeutics Inc (RLAY) has a beta value of 1.60, and an average true range (ATR) of 0.50. Analysts have given the company’s stock an average 52-week price target of $18, forecast between a low of $16 and high of $20. Looking at the price targets, the low is -270.37% off current price level while to achieve the yearly target high, price needs to move -362.96%. Nonetheless, investors will most likely welcome a -316.67% jump to $18 which is the analysts’ median price.
If we refocus on Relay Therapeutics Inc (NASDAQ:RLAY), historical trading data shows that trading volumes averaged 3.15 over the past 10 days and 2.14 million over the past 3 months. The company’s latest data on shares outstanding shows there are 166.89 million shares.
The 26.25% of Relay Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 73.18% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 14.95 million on 2024-12-31, giving us a short ratio of 5.6. The data shows that as of 2024-12-31 short interest in Relay Therapeutics Inc (RLAY) stood at 1084.0 of shares outstanding, with shares short rising to 11.93 million registered in 2024-11-29. Current price change has pushed the stock 4.85% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RLAY stock continues to rise going into the next quarter.
